Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium

December 9, 2010 By Bio-Medicine.Org

BRIDGEWATER, N.J., Dec. 9, 2010 /PRNewswire-FirstCall/ —
Sanofi-aventis (EURONEXT: SAN and NYSE:
SNY
) announced today that the final survival analysis (10-year
follow-up) of the BCIRG001 study that included a Taxotere®
(docetaxel) Injection Concentrate chemotherapy treatment regimen in
the adjuvant breast cancer setting, as well as data from iniparib
(BSI-201) pre-clinical and clinical breast cancer studies will be
featured during the 33rd Annual San Antonio Breast Cancer Symposium
(SABCS) in San Antonio, Texas from December 8 to 12, 2010.
 

During SABCS, the final (10-year follow up) survival analysis of
the BCIRG001 study that included sanofi-aventis’ chemotherapy drug
Taxotere, in combination with doxorubicin and cyclophosphamide, in
women with operable node-positive breast cancer will be presented.
Also being presented are data from pre-clinical and clinical
studies involving the sanofi-aventis investigational compound
iniparib (BSI-201), which is being studied in breast cancer.
 Iniparib is a novel investigational small molecule with poly
(ADP-ribose) polymerase (PARP) inhibitory activity.

Key events at SABCS include: Taxotere Data:Abstract
#S4-3

Friday, Dec. 10

3:45 PM CSTAn oral presentation featuring final results from
the ten-year follow-up analysis of the BCIRG 001 trial Iniparib
Data:Abstract #P5-06-09

Phase 1b/2 MBC trial

Saturday, Dec. 11

5:30 – 7:30 PM CSTData from a Phase 1b study to assess the
safety and tolerability of the investigational compound iniparib
(BSI-201) in combination with irinotecan in patients with
metastatic breast cancer (MBC)Iniparib Data:Abstract #
P6-04-12

Activity in TNBC Cell lines

Sunday, Dec. 12

7:00 – 8:30 AM CSTData from a preclinical study assessing the
cell cycle effects of the investigational compound iniparib
(BSI-201) in combination

‘/>”/>

SOURCE

Related Articles Read More >

A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
How Abbott developed the first-of-its-kind Infinity DBS system
Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe